VX 15

Drug Profile

VX 15

Alternative Names: Anti-SEMA4D antibody - Vaccinex; moAb VX15/2503; VX15; VX15/2503

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaccinex
  • Developer Emory University; Merck KGaA; Teva Pharmaceutical Industries; Vaccinex
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD100 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Phase I/II Non-small cell lung cancer
  • Phase I Colorectal cancer; Pancreatic cancer
  • No development reported Multiple sclerosis; Solid tumours

Most Recent Events

  • 07 Feb 2018 Jonsson Comprehensive Cancer Center in collaboration with National Cancer Institute plans a phase I trial for Melanoma (Late-stage disease) in USA , (NCT03425461)
  • 21 Dec 2017 Vaccinex plans a phase I trial for Pancreatic cancer (Monotherapy, Combination therapy, First line-therapy, Late-stage disease) and Colorectal cancer (Monotherapy, Combination therapy, Late stage disease, Metastatic disease, First-line therapy) in USA (IV) (NCT03373188)
  • 15 Dec 2017 Phase-I clinical trials in Colorectal cancer (First-line therapy, Late-stage disease, Metastatic disease, Combination therapy, Monotherapy) in USA (IV) (NCT03373188)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top